Loading...

ABIVAX Société Anonyme

DB:2X1
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2X1
DB
€101M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
2X1 Share Price and Events
7 Day Returns
-0.2%
DB:2X1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
34.7%
DB:2X1
-10.2%
DE Biotechs
-6%
DE Market
2X1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ABIVAX Société Anonyme (2X1) -0.2% 11.1% -5.4% 34.7% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 2X1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 2X1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
2X1
Industry
5yr Volatility vs Market

Value

 Is ABIVAX Société Anonyme undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ABIVAX Société Anonyme. This is due to cash flow or dividend data being unavailable. The share price is €9.97.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ABIVAX Société Anonyme's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ABIVAX Société Anonyme's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2X1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.29
ENXTPA:ABVX Share Price ** ENXTPA (2019-04-18) in EUR €10.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ABIVAX Société Anonyme.

DB:2X1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ABVX Share Price ÷ EPS (both in EUR)

= 10.14 ÷ -1.29

-7.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIVAX Société Anonyme is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ABIVAX Société Anonyme is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ABIVAX Société Anonyme's expected growth come at a high price?
Raw Data
DB:2X1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-15.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ABIVAX Société Anonyme, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ABIVAX Société Anonyme's assets?
Raw Data
DB:2X1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.12
ENXTPA:ABVX Share Price * ENXTPA (2019-04-18) in EUR €10.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2X1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ABVX Share Price ÷ Book Value per Share (both in EUR)

= 10.14 ÷ 4.12

2.46x

* Primary Listing of ABIVAX Société Anonyme.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIVAX Société Anonyme is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ABIVAX Société Anonyme's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ABIVAX Société Anonyme has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ABIVAX Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-15.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ABIVAX Société Anonyme expected to grow at an attractive rate?
  • ABIVAX Société Anonyme's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ABIVAX Société Anonyme's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • ABIVAX Société Anonyme's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2X1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2X1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -15.8%
DB:2X1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 9.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2X1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2X1 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 22 -26 1
2022-12-31 1 -45 1
2021-12-31 1 -42 1
2020-12-31 49 -8 14 2
2019-12-31 26 -18 -18 3
DB:2X1 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -16
2018-09-30 1 -14
2018-06-30 1 -11 -13
2018-03-31 1 -10 -12
2017-12-31 0 -8 -11
2017-09-30 0 -11
2017-06-30 0 -11 -12
2017-03-31 0 -14 -13
2016-12-31 0 -16 -14
2016-09-30 0 -16
2016-06-30 0 -24 -17
2016-03-31 0 -19 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ABIVAX Société Anonyme's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • ABIVAX Société Anonyme's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2X1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from ABIVAX Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2X1 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.19 -2.19 -2.19 1.00
2022-12-31 -3.77 -3.77 -3.77 1.00
2021-12-31 -3.49 -3.49 -3.49 1.00
2020-12-31 3.02 3.02 3.02 1.00
2019-12-31
DB:2X1 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31
2018-09-30
2018-06-30 -1.29
2018-03-31 -1.21
2017-12-31 -1.13
2017-09-30 -1.16
2017-06-30 -1.19
2017-03-31 -1.33
2016-12-31 -1.47
2016-09-30 -1.62
2016-06-30 -1.77
2016-03-31 -1.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ABIVAX Société Anonyme will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess ABIVAX Société Anonyme's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ABIVAX Société Anonyme has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ABIVAX Société Anonyme performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ABIVAX Société Anonyme's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ABIVAX Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ABIVAX Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ABIVAX Société Anonyme's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ABIVAX Société Anonyme's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ABIVAX Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2X1 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.80 -15.80 4.00 15.90
2018-09-30 0.82 -14.36 3.96 7.95
2018-06-30 0.85 -12.92 3.92
2018-03-31 0.60 -12.07 3.85
2017-12-31 0.36 -11.22 3.78
2017-09-30 0.19 -11.40 3.67
2017-06-30 0.02 -11.58 3.55
2017-03-31 0.08 -12.95 3.55
2016-12-31 0.15 -14.31 3.56
2016-09-30 0.10 -15.68 3.71
2016-06-30 0.06 -17.06 3.86
2016-03-31 0.14 -16.51 3.64
2015-12-31 0.23 -15.96 3.42
2015-09-30 0.36 -13.78 3.21
2015-06-30 0.50 -11.60 2.99
2015-03-31 0.34 -8.34 2.40
2014-12-31 0.19 -5.08 1.82
2013-12-31 -0.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ABIVAX Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ABIVAX Société Anonyme has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ABIVAX Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ABIVAX Société Anonyme's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ABIVAX Société Anonyme has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ABIVAX Société Anonyme's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ABIVAX Société Anonyme's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ABIVAX Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ABIVAX Société Anonyme's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ABIVAX Société Anonyme's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ABIVAX Société Anonyme has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ABIVAX Société Anonyme Company Filings, last reported 3 months ago.

DB:2X1 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31
2018-09-30 41.09 0.00 7.58
2018-06-30 41.09 0.00 7.58
2018-03-31 41.09 0.00 7.58
2017-12-31 48.18 0.26 17.03
2017-09-30 48.18 0.26 17.03
2017-06-30 51.17 0.33 16.37
2017-03-31 51.17 0.33 16.37
2016-12-31 56.72 0.32 22.99
2016-09-30 56.72 0.32 22.99
2016-06-30 62.88 0.39 28.12
2016-03-31 62.88 0.39 28.12
2015-12-31 71.74 0.44 39.13
2015-09-30 71.74 0.44 39.13
2015-06-30 80.54 2.12 53.68
2015-03-31 80.54 2.12 53.68
2014-12-31 33.94 2.09 2.92
2013-12-31 0.03 0.00 0.04
  • ABIVAX Société Anonyme has no debt.
  • ABIVAX Société Anonyme currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ABIVAX Société Anonyme has less than a year of cash runway based on current free cash flow.
  • ABIVAX Société Anonyme has less than a year of cash runway if free cash flow continues to reduce at historical rates of -27.5% each year.
X
Financial health checks
We assess ABIVAX Société Anonyme's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ABIVAX Société Anonyme has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ABIVAX Société Anonyme's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ABIVAX Société Anonyme dividends.
If you bought €2,000 of ABIVAX Société Anonyme shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ABIVAX Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ABIVAX Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2X1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2X1 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ABIVAX Société Anonyme has not reported any payouts.
  • Unable to verify if ABIVAX Société Anonyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ABIVAX Société Anonyme's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ABIVAX Société Anonyme has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ABIVAX Société Anonyme's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ABIVAX Société Anonyme afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ABIVAX Société Anonyme has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ABIVAX Société Anonyme's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hartmut Ehrlich
COMPENSATION €371,380
TENURE AS CEO 5.3 years
CEO Bio

Prof. Dr. Hartmut J. Ehrlich, M.D. has been the Chief Executive Officer of ABIVAX S.A. since December 04, 2013. Prof. Dr. Ehrlich is a physician and global leader with 30 years in academia and in the biopharmaceutical industry, 20 of which were in product development at Baxter and Sandoz (now Novartis). He worked in the United States (Eli Lilly and Indiana University, Dept. of Medicine), the Netherlands (Central Laboratory of the Dutch Red Cross), Germany (Max Planck Foundation, Sandoz, Baxter), Switzerland (Sandoz), Austria (Baxter) and France (ABIVAX). Over the past 7 years before joining ABIVAX, he successfully built and advanced Baxter BioScience’s R&D portfolio with over 50 programs in preclinical and clinical development. He drove the regulatory approval of key biologics in the specialty areas of Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines. Prof. Dr. Ehrlich has authored and co-authored over 120 peer-reviewed articles and book chapters. In 2011, Prof. Dr. Ehrlich was named “Professor” by the Austrian President and the Austrian Minister for Science and Research and he received the title of “Adjunct Professor” of the Danube University Krems, Lower Austria in 2013.

CEO Compensation
  • Hartmut's compensation has increased whilst company is loss making.
  • Hartmut's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the ABIVAX Société Anonyme management team in years:

2.3
Average Tenure
  • The tenure for the ABIVAX Société Anonyme management team is about average.
Management Team

Philippe Pouletty

TITLE
Founder & Chairman
AGE
60

Hartmut Ehrlich

TITLE
Chief Executive Officer
COMPENSATION
€371K
TENURE
5.3 yrs

Didier Blondel

TITLE
VP, CFO & Board Secretary
TENURE
2.3 yrs

Raquel Lizarraga

TITLE
Investor Relations Manager

Anne Pascard

TITLE
Human Resources Manager

Pierre Courteille

TITLE
VP, Chief Commercial Officer & VP of Business Development

Jean-Marc Steens

TITLE
VP & Chief Medical Officer

Alex Pearce

TITLE
VP & Head of Regulatory Affairs
TENURE
0.9 yrs

Alain Chevallier

TITLE
Senior Advisor
AGE
65
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the ABIVAX Société Anonyme board of directors in years:

4.8
Average Tenure
61.5
Average Age
  • The tenure for the ABIVAX Société Anonyme board of directors is about average.
Board of Directors

Philippe Pouletty

TITLE
Founder & Chairman
AGE
60
TENURE
4.3 yrs

Corinna Bonsen-Thomas

TITLE
Director
TENURE
1.8 yrs

Ian McGowan

TITLE
Chairman of Scientific Advisory Board
TENURE
0.8 yrs

Joy Amundson

TITLE
Director
COMPENSATION
€2K
AGE
63
TENURE
4.8 yrs

Claude Bertrand

TITLE
Director
COMPENSATION
€3K
AGE
56
TENURE
5.1 yrs

Jean-Jacques Bertrand

TITLE
Director
COMPENSATION
€6K
AGE
79
TENURE
5.1 yrs

Christian Pierret

TITLE
Director
COMPENSATION
€7K
TENURE
5.1 yrs

Jean-Paul Prieels

TITLE
Member of Scientific Advisory Board
COMPENSATION
€3K

Luc Teyton

TITLE
Member of Scientific Advisory Board

Christoph Huber

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ABIVAX Société Anonyme's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ABIVAX Société Anonyme has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. Its principal products include ABX 464 that is in Phase II clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS; ABX 203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX 196, an art immune enhancer candidate that has completed Phase I clinical trials for iNKT cells. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis. In addition, the company’s pre-clinical programs comprise ABX 220 for the treatment of Dengue fever; ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and ABX 311 for the treatment of Chikungunya. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute; and a partnership with the Cuban Centro de Ingeneria Genetica y de Biotecnologia. The company was incorporated in 2013 and is headquartered in Paris, France.

Details
Name: ABIVAX Société Anonyme
2X1
Exchange: DB
Founded: 2013
€101,205,129
9,980,782
Website: http://www.abivax.com
Address: ABIVAX Société Anonyme
5, rue de la Baume,
Paris,
Ile-de-France, 75008,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ABVX Common Stock Euronext Paris FR EUR 26. Jun 2015
OTCPK AAVX.F Common Stock Pink Sheets LLC US USD 26. Jun 2015
DB 2X1 Common Stock Deutsche Boerse AG DE EUR 26. Jun 2015
LSE 0RA9 Common Stock London Stock Exchange GB EUR 26. Jun 2015
Number of employees
Current staff
Staff numbers
25
ABIVAX Société Anonyme employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.